Decitabine

Decitabine
Product Description

Pfanstiehl offers a wide range of products which includes decitabine. Features: it is approved in 2006 by fda for treatment of patients for with myelodysplastic syndromes (mds), a group of diseases of the bone marrow characterized by the production of poorly functioning and immature blood cells. Over time, mds can progress to acute leukemia, or aml. Contact us for more information.

Read more Show less

Pfanstiehl

  • Country/Region:
    United States
  • On CPHI since:
    2017
Company types
Manufacturer/Innovator
View company profile
Specifications
  • Selling Points
    Product Features; Quality Service
  • Supplied from
    United States
More specifications Fewer specifications
Sales Markets
Show more Show less

Pfanstiehl

  • Country/Region:
    United States
  • On CPHI since:
    2017
Company types
Manufacturer/Innovator
View company profile

More Products from Pfanstiehl (2)

  • Cytarabine

    Product Cytarabine

    Pfanstiehl offers a wide range of products which includes cytarabine. Features: it is mainly used in the treatment of acute myeloid leukemia (aml) and acute lymphocytic leukemia (all) and in lymphomas where it is the backbone of induction chemotherapy. Contact us for more information.
  • Decitabine

    Product Decitabine

    Small molecule API